Health

With high costs and similar benefits, the use of new psychoactive drugs is low


prescription drugs

Credit: Pixabay/CC0 Public Domain

Several new neuroleptic drugs for conditions such as multiple sclerosis (MS), Parkinson’s disease, and migraines have received Food and Drug Administration (FDA) approval over the past decade. via. However, with most drugs having higher out-of-pocket costs and similar benefits to existing, less expensive drugs, only a small percentage of people with neurological disease are treated with these drugs. This new drug, according to a study published on November 30, 2022, the online issue of neurology.

Study author Brian C. Callaghan, MD, MS, University of Michigan Health in Ann Arbor and a member of the American Academy of Neurology, said: found that less than 20% were being treated with the new drug.” . “For new, high-cost drugs that are as effective as older drugs, limited use may be appropriate. However, future studies are needed to see if high cost are barriers to new drugs that can really make a difference for people with neurological diseases.”

For the study, the researchers used a private insurance complaint database to identify those with 11 neurological conditions and a prescription for a new or existing drug. The study included 2.3 million people with migraine, 76,990 people with MS, 67,917 people with Parkinson’s disease, 57,259 people with orthostatic hypertension, 22,936 people with myasthenia gravis, 6,257 people with the disorder. tardive, 4,180 people suffer from migraine. amyotrophic lateral sclerosis (ALS), 2,277 had Huntington’s disease, 267 had transthyretin amyloidosis, 163 had Duchenne’s disease, and 10 had spinal muscular atrophy.

The researchers then looked at the use of new drugs versus existing drugs. The newly identified drugs are those that were approved by the FDA between 2014 and 2018. They include erenumab, fremanezumab and galcanezumab for migraines, ocrelizumab and peginterferon beta-1a for MS, pimavanserin and safinamide for Parkinson’s disease, droxidopa for orthostatic hypertension, eculizumab for myasthenia gravis, edaravone for ALS, deutetrabenazine and valbenazine for both Huntington’s and tardive dyskinesia, patisiran and inotersen for amyloidosis transthyretin, eteplirsen and deflazacort for Duchenne’s disease and nusinersen for spinal muscular atrophy.

When calculating the proportion of people taking new versus all drugs for each condition, the researchers found that less than 20 percent of participants were taking the new drug for all conditions except dyskinesia. late, this rate is 32%.

The researchers also calculated the average out-of-pocket cost for a 30-day supply of each. medicine. The two most expensive drugs are edaravone for ALS, which costs $713 per month, and eculizumab for myasthenia gravis, which is $91 per month. Overall, out-of-pocket costs and total costs for new medicine significantly larger than existing drugs. Out-of-pocket costs for new drugs are also very variable and unpredictable compared to the costs for existing drugs.

Callaghan notes that new drugs for rare diseases spinal muscular atrophy and transthyretin amyloidosis have dramatically changed care, allowing stabilization of progressive and debilitating diseases. “Unfortunately, the small number of people in the study with these diseases did not allow the authors to draw conclusions about the impact of cost on the use of these game-changing drugs,” he said. .”

“We live in an age where new treatments offer hope to people with neurological diseases and disorders,” says Orly Avitzur, MD, MBA, FAAN, President of the American Academy of Neurology. “However, even current prescription drugs can be expensive, and drug prices continue to rise. In order for neurologists to be able to provide people with the highest quality care, it is imperative that the best types of medicine are available. New drugs must be accessible and affordable to those who need them.”

One limitation of the study was the short follow-up period for some recently approved drugs. Another limitation is the small number of people in the study with rare diseases.

More information:
Evan L Reynolds et al, Cost and use of new-to-market psychoactive drugs, neurology (2022). 10.1212/WNL.0000000000201627. n.neurology.org/content/early/… WNL.0000000000201627

quote: With high costs and similar benefits, low use of new psychoactive drugs (2022, Nov. 30) retrieved Nov. 30, 2022 from https://medicalxpress.com/news/2022 -11-high-similar-benefits-neurology-drugs. html

This document is the subject for the collection of authors. Other than any fair dealing for private learning or research purposes, no part may be reproduced without written permission. The content provided is for informational purposes only.

news5s

News5s: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, Sports...at the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button